SCHEMBL8567440

SCHEMBL8567440

COC(OC)(OC)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21879331 0.72 LMNA (0.38)
SCHEMBL24066870 0.72 ALDH1A1 (0.40) ALDH1A1
SCHEMBL4442945 0.71 ALDH1A1 (0.46) ALDH1A1
SCHEMBL10463 0.67
SCHEMBL17729837 0.67
SCHEMBL1306743 0.67 ALDH1A1 (0.33) ALDH1A1
SCHEMBL1116379 0.67 ALDH1A1 (0.33) ALDH1A1
SCHEMBL9931 0.67
SCHEMBL6295216 0.67 ALDH1A1 (0.33) ALDH1A1
SCHEMBL14561703 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335394-A1 Use Of Methanol And Prodrugs Thereof In Therapy LUDWIG INST FOR CANCER RES LTD (CH) 2024-10-10 US claimed
EP-4370105-A1 USE OF METHANOL AND PRODRUGS THEREOF IN THERAPY Ludwig Institute for Cancer Research Ltd (CH) 2024-05-22 EP claimed
WO-2023288299-A1 USE OF METHANOL AND PRODRUGS THEREOF IN THERAPY FARBER PARTNERS, LLC (US) 2023-01-19 WO claimed
EP-0587440-A2 Catalyst component for the polymerisation of olefins and process for preparing olefin polymers using same NIPPON OIL COMPANY, LIMITED (JP) 1994-03-16 EP claimed
US-20240335394-A1 Use Of Methanol And Prodrugs Thereof In Therapy LUDWIG INST FOR CANCER RES LTD (CH) 2024-10-10 US disclosed
EP-4370105-A1 USE OF METHANOL AND PRODRUGS THEREOF IN THERAPY Ludwig Institute for Cancer Research Ltd (CH) 2024-05-22 EP disclosed
WO-2023288299-A1 USE OF METHANOL AND PRODRUGS THEREOF IN THERAPY FARBER PARTNERS, LLC (US) 2023-01-19 WO disclosed
WO-2023288299-A1 USE OF METHANOL AND PRODRUGS THEREOF IN THERAPY FARBER PARTNERS, LLC (US) 2023-01-19 WO disclosed
US-5744678-A NICKEL COMPOUND, ORGANOPHOSPHORUS COMPOUND, ORGANOALUMINUM COMPOUND, CARBON-HALOGEN COMPOUNDS; CATALYST SELECTIVITY NIPPON OIL CO., LTD. (JP) 1998-04-28 US disclosed
US-5728641-A Catalyst component for the polymerization of olefins NIPPON OIL COMPANY, LIMITED (JP) 1998-03-17 US disclosed
EP-0758563-A1 OLEFIN OLIGOMERIZATION CATALYST AND PROCESS FOR THE PREPARATION OF OLEFIN OLIGOMER USING IT NIPPON OIL COMPANY, LTD. (JP) 1997-02-19 EP disclosed
US-5556821-A Catalyst component for the polymerization of olefins NIPPON OIL COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0587440-A2 Catalyst component for the polymerisation of olefins and process for preparing olefin polymers using same NIPPON OIL COMPANY, LIMITED (JP) 1994-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335394-A1 Use Of Methanol And Prodrugs Thereof In Therapy MYD88, MRGPRX2, MRGPRX1 ALDH1A1 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.